First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology（2022）

引用 28|浏览27

暂无评分

摘要

In patients with advanced renal cell carcinoma without prior nephrectomy and with an evaluable primary tumor, combination immunotherapy with nivolumab plus ipilimumab offers a benefit in renal tumor reduction and survival over sunitinib.

查看译文

关键词

Advanced renal cell carcinoma,CheckMate 214,Cytoreductive nephrectomy,Ipilimumab,Nivolumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要